AG-SITAGLIPTIN DIN 02535513
Status: Marketed
Holder: ANGITA PHARMA INC.
Health Canada record
| Active ingredient(s) | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 25 MG |
|---|---|
| Dosage form | Tablet |
| Route | Oral |
| Schedule | PRESCRIPTION |
| Class | Human |
| ATC | A10BH01 SITAGLIPTIN |
| Original market date | 01-Dec-2023 |
| Current status date | 01-Dec-2023 |
| Source | Health Canada DPD |
Establishment licence of the holder
Angita Pharma Inc. — licence 101870, currently licensed, last inspection rating C (2025-01-13).
No Canadian shortage report is currently matched to this DIN.
Other Canadian products containing SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE)
| DIN | Product | Company | Form | Strength | Status |
|---|---|---|---|---|---|
| 02535521 | AG-SITAGLIPTIN | ANGITA PHARMA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG | Marketed |
| 02535548 | AG-SITAGLIPTIN | ANGITA PHARMA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 100 MG | Marketed |
| 02557711 | AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN | ANGITA PHARMA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02557746 | AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN | ANGITA PHARMA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02557738 | AG-SITAGLIPTIN HYDROCHLORIDE / METFORMIN | ANGITA PHARMA INC. | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02529866 | AURO-SITAGLIPTIN | AURO PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 25 MG | Marketed |
| 02529874 | AURO-SITAGLIPTIN | AURO PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG | Marketed |
| 02529882 | AURO-SITAGLIPTIN | AURO PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 100 MG | Marketed |
| 02547805 | AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE | AURO PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02547813 | AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE | AURO PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02547821 | AURO-SITAGLIPTIN HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE | AURO PHARMA INC | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
| 02534134 | JAMP SITAGLIPTIN | JAMP PHARMA CORPORATION | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 25 MG | Marketed |
| 02534150 | JAMP SITAGLIPTIN | JAMP PHARMA CORPORATION | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 100 MG | Marketed |
| 02534142 | JAMP SITAGLIPTIN | JAMP PHARMA CORPORATION | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG | Marketed |
| 02556189 | JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN | JAMP PHARMA CORPORATION | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 500 MG | Marketed |
| 02556197 | JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN | JAMP PHARMA CORPORATION | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 850 MG | Marketed |
| 02556200 | JAMP SITAGLIPTIN HYDROCHLORIDE / METFORMIN | JAMP PHARMA CORPORATION | Tablet | SITAGLIPTIN (SITAGLIPTIN HYDROCHLORIDE MONOHYDRATE) 50 MG; METFORMIN HYDROCHLORIDE 1000 MG | Marketed |
Notices of Compliance
| NOC | Date | Submission | Reason |
|---|---|---|---|
| 30142 | 2023-02-16 | Abbreviated New Drug Submission (ANDS) | Administrative: Licensing Agreement Between Two Companies |